Incidental gallbladder cancer (IGBCA), or malignancy diagnosed histologically after an elective cholecystectomy for presumed benign disease, 1,2 is increasing in incidence, a likely consequence of the rising number of elective cholecystectomies. 1, 3 Re-exploration and definitive resection are recommended for selected patients with invasive tumors and without evidence of disseminated disease. The objective of resection is to treat likely areas of locoregional residual disease (RD). Although it is widely assumed that such operations improve survival, 4 their benefit has never been demonstrated in prospective studies.
Previous publications have shown RD in up to 72% of patients undergoing re-exploration. [5] [6] [7] However, disease extent in these studies varies considerably, from gross metastatic disease recognized during re-exploration to unsuspected microscopic disease found only after a complete resection. [8] [9] [10] [11] [12] Lymph node involvement and distant metastases change the disease stage and decrease survival in patients with IGBCA. Likewise, some studies have suggested that RD in the gallbladder fossa also confers reduced survival; however, it has not been defined if all possible areas of RD (ie, local, regional, or distant) have the same impact on survival, especially for patients who do not have macroscopic metastatic disease and undergo complete resection. In addition, it is unknown if the expected decreased survival observed in these patients is a consequence only of stage migration after definitive resection.
The aims of this study were to describe the pattern of RD in patients submitted to complete resection for IGBCA and to determine the impact of the anatomic site of RD on survival. We further sought to correlate preoperative clinical and pathologic variables with the likelihood of RD, and determine if RD was associated with survival.
METHODS
Subjects and data collection After approval by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center (MSKCC), records of all patients with IGBCA who underwent re-exploration between 1998 and 2009 were collected from a prospectively created database and analyzed. This analysis included only patients who underwent a complete or R0 resection of all disease, based on the results of the re-exploration and definitive resection. Recorded data incorporated patient demographics, operative procedures, perioperative outcomes, tumor histopathology and staging, follow-up, recurrence patterns, and survival. Incidental gallbladder cancer was defined as unsuspected gallbladder cancer (GBCA) diagnosed histologically after cholecystectomy performed for presumed benign disease.
The authors' approach to patient selection and evaluation of GBCA has been reported previously. 2, 8, [13] [14] [15] All patients were restaged with physical examination and imaging studies (thoracic and abdominal/pelvic CT, MRI, and/or 18 F-fluorodeoxyglucose PET-CT [ 18 FDG PET-CT]), which included those performed at MSKCC and at referring hospitals. Imaging studies were obtained according to surgeon preference and were reviewed at a weekly multidisciplinary hepatopancreatobiliary conference. Re-exploration and definitive resection were recommended to all patients with tumor invasion to at least the muscularis propria layer (T1b) and without evidence of stage IV disease after restaging. Patients with T1a IGBCA were not included in this analysis.
Pathologic examination
The surgical pathology material obtained from the initial cholecystectomy was reviewed before re-exploration to confirm the final diagnosis in all patients and was evaluated for depth of tumor invasion (T stage), tumor histology and grade of differentiation, presence of perineural and/or lymphovascular invasion, inflammation, cystic duct margin, and the presence of adjacent lymph nodes. Tumor involvement of any resection margin was defined as positive. Lymph node metastasis was defined as tumoral involvement in at least 1 lymph node resected. Of note, some patients had involved cystic duct lymph nodes based on analysis of the initial cholecystectomy specimen but had no residual disease found at definitive resection; these patients were classified as N1 but without residual disease. On the other hand, patients with nodal disease after definitive resection were staged as N1 or N2 with residual disease. Depth of tumor invasion and lymph node metastases (N1 vs N2) were defined by the American Joint Committee on Cancer (AJCC) staging manual (7 th edition). 16 Of note, in patients with residual disease in the gallbladder fossa, the T stage based on the initial cholecystectomy was maintained because the current AJCC staging system makes no provision for making such changes. Histologic types were divided into adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, and undifferentiated. Histologic differentiation was divided into well, moderately, and poorly differentiated.
Operative approach
The authors' operative approach to resection of GBCA has been documented previously. [13] [14] [15] Staging laparoscopy was performed selectively before laparotomy to exclude metastatic disease. 2 Patients who appeared to have localized and resectable disease at laparoscopy underwent a laparotomy. Neoadjuvant chemotherapy or chemoradiation was not used in any patient. Open exploration included mobilization and palpation of the liver, duodenum, head of the pancreas, and retroperitoneum, and ultrasonography of the liver. Biopsies were taken of any The extent of liver resection was based on the apparent disease extent and proximity to major inflow pedicles at exploration. Major hepatectomy was defined as a right or left hepatectomy or extended hepatectomy. Minor hepatectomy was defined as resection of segments 4b and 5 or less. Common bile duct resection was performed selectively to achieve clear margins when there was definite or suspected involvement. The lymphadenectomy included nodal tissue in the porta hepatis and portocaval basins and along the common hepatic artery. Port site resection was performed selectively in accordance with surgeon's preference; bile duct resection was performed routinely during the first part of this series, but it is currently performed selectively only when the cystic duct margin is positive and it is not possible to achieve a negative margin. Operative and perioperative outcomes were recorded. Surgical mortality was defined as death resulting from postoperative complications within 90 days of surgery.
Residual disease
Residual disease after complete resection was defined by intraoperative findings and confirmed by the final pathology report. Specifically, 4 sites of possible RD were classified: liver (gallbladder bed and/or discontinuous liver involvement), bile duct, regional lymph nodes, and other sites. residual disease at other sites included peritoneal disease not apparent at the time of definitive resection or involvement of port sites, when these areas were empirically resected; in both of these instances, microscopic distant disease was not suspected during surgery but was identified only after final histologic examination. Local RD included gallbladder bed without discontinuous liver involvement; regional RD included involvement of bile duct/cystic duct stump and/or regional lymph nodes; distant RD included discontinuous liver involvement (liver metastases), and peritoneal or port site metastases.
Final disease staging was based on the 7 th edition of the AJCC manual and included information related to the initial cholecystectomy and re-exploration. 16 Patients with incidental nodal or distant disease (ie, port site or discontiguous liver metastases) were staged accordingly; however, although this staging system clearly defines lymph node involvement and distant metastatic disease, there is no consensus about how the T stage should be classified (or reclassified) in patients who are initially diagnosed with a T1b or T2 IGBCA and subsequently found to have RD in the gallbladder bed. 15 Because it cannot be determined if RD in this setting represents local extension from the primary tumor (misclassification of the initial T stage), tumor cell spillage from the initial cholecystectomy, or metastatic disease, the original T stage obtained at the time of cholecystectomy was maintained.
Follow-up, recurrence, and survival Disease status at last follow-up was recorded. Diseasespecific survival (DSS) was defined as the interval between the date of the definitive operation and the date of last follow-up or death. Only death from disease was considered an event in the analysis of DSS. Disease-free survival (DFS) was defined as the interval between the date of the definitive operation and the date of recurrence or last follow-up in patients without recurrence. One patient was not considered in the analysis of DFS because the date and pattern of recurrence had not been recorded.
Recurrence was defined as any sign of recurrent disease (clinical, radiographic, and/or pathological). Clinical proof of recurrence was documented by evidence of disease at physical examination (ie, abdominal mass, lymph node enlargement). All recurrences initially documented clinically were confirmed by biopsy or serial radiology. Radiologic proof of recurrence was documented with sequential imaging demonstrating progression of disease. The impact of RD on cancer-specific survival was assessed, both overall and stratified by site (ie, local, regional, distant). To further assess the clinical impact of local residual disease, patients with T2N0 GBCA without RD, T3N0 without RD, T1b-2N0 with RD in the gallbladder bed, and T3N0 with RD in the gallbladder bed (ie, local RD only) were compared.
Statistical analysis
Categorical variables were summarized using proportions, and continuous variables were expressed as the mean (AEstandard deviation) and median (range). Characteristics of patients with residual and no-residual disease were compared using the Fisher exact test for categorical variables and Wilcoxon signed rank test for continuous variables. Survival curves were constructed by the Kaplan-Meier method and were compared using the log-rank test. A univariate Cox proportional hazards regression model was used in all patients treated with complete resection (n ¼ 116) to identify factors Table 1) . Re-examination of the initial cholecystectomy specimen showed invasion into the perimuscular connective tissue (T2) in most patients (n ¼ 62, 53.4%), 108 (93.1%) patients had adenocarcinoma, and 61 (53.5%) had a moderately differentiated tumor. Lymphovascular invasion was specifically analyzed in 87 patients and was positive in 41 (47.1%); perineural invasion was observed in 42.2% (35 of 83). A positive margin after the initial cholecystectomy was reported in 46 (40%) of 115 patients and was unknown in 1 patient; the gallbladder bed margin was most commonly involved (n ¼ 26), followed by the cystic duct (n ¼ 19), and both in 1 patient. The cystic lymph node was involved by tumor in 13 patients, was benign in 13, and was either not examined or not present in the remainder (Table 1 ).
All patients (n ¼ 116) were restaged with at least 1 cross-sectional imaging study before re-exploration: CT was used in 81 patients, MRI/cholangio-MRI in 50 patients, 18 FDG PET-CT in 24 patients, and abdominal ultrasound in 12 patients. Sixty-seven patients were restaged with 1 modality, 45 with 2, and 4 with 3.
Definitive treatment
The median time between cholecystectomy and re-exploration was 2 months (range 0.4 to 35 months). Most patients underwent liver resection (n ¼ 114, 98.3%), bile duct resection (n ¼ 71, 61.2%), and lymphadenectomy (n ¼ 116, 100%) as part of their definitive treatment. A combined resection of liver and bile duct was performed in 69 (59.5%) patients; 2 patients (1.7%) were treated with common bile duct resection and lymphadenectomy (Table 1) .
Incidence and location of residual disease Residual disease was found in 82 of 135 (60.7%) patients with IGBCA submitted to re-exploration and in 63 of 116 (54.3%) patients undergoing resection with curative intent. In this latter subgroup, RD involved the liver in 43 patients (68.3%) (gallbladder bed in 38 and gallbladder bed plus discontinuous liver disease in 5), lymph nodes in 29 patients (46%), common bile duct in 14 patients (22.2%), and other sites in 13 patients (20.6%) (peritoneum [n ¼ 6], laparoscopic port sites [n ¼ 6], and peritoneum plus port sites [n ¼ 1]). Thirty-eight (60.3%) patients had RD at 1 site, 16 (25.4%) at 2, 7 (11.1 %) at 3, and 2 (3.2%) at 4 sites. Residual disease was only local in 18 patients, regional in 27 patients, and distant in 18 patients; in the latter 18 patients, microscopic metastatic disease was identified only after histologic analysis of the final resected specimen. (Table 2) .
Follow-up, recurrence, and survival After definitive resection, 65 of 116 patients (56%) suffered recurrence at a median time of 11 months (range 2 to 127 months). Recurrence was significantly more frequent in patients with RD (n ¼ 46, 73%) compared with patients without RD (n ¼ 19, 35.8%) (p < 0.0001). However, the pattern of disease recurrence after definitive resection was similar (p ¼ 0.4) ( Table 3 ). The final status after a median follow-up of 27.3 months (range 0.4 to 170.3 months) was as follows: 56 patients were dead of disease, 42 had no evidence of disease, 9 were alive with disease, 4 died of unknown causes, 3 died of other causes, and 2 died of postoperative complications. Median DFS was 25.9 months (95% CI 13 to 38.8 months) (Fig. 1A) , and was higher in patients without RD (median 93.4 months; 95% CI, 67.1 to 119.7 months) compared with patients with RD (median 11.2 months; 95% CI, 6.9 to 15.5 months) (Fig. 1B, (Fig. 1C) , and was also higher in patients without RD (median not reached) compared with patients with RD (median, 25.2 months; 95% CI 14.8 to 35.6 months) (Fig. 1D, p < 0.0001) . Of note, DFS did not differ among patients with residual disease in local (median 9.3 months; 95% CI, 6.8 to 11.8 months), regional (median 16.8 months; 95% CI 7 to 26.7 months) or distant sites (median 8.7 months; 95% CI 3.4 to 13.9 months), (p ¼ 0.25) (Fig. 2A) . Similarly, DSS did not differ based on site of recurrence: local (median 39.2 months; 95% CI 11.5 to 66.9 months), regional (median 30.9 months; 95% CI, 17.3 to 44.4 months), distant (median 23.8 months; 95% CI, 14.8 to 32.8 months) (p ¼ 0.87) (Fig. 2B) .
To fully assess the impact of local RD on survival, patients with and without RD were compared directly. For the purposes of this analysis, patients with T2N0 (n ¼ 30) and T3N0 (n ¼ 9) tumors and no RD were compared with patients with comparable T stage and local RD (ie, gallbladder fossa) only. Median DFS of patients with a T2N0 GBCA and no RD was not reached, and was 93.4 months (95% CI 0 to 235 months) in patients with a T3N0 GBCA and no RD; by contrast, in patients with local RD, DFS was 32 months (95% CI 4.6 to 59.5 months) patients with T1b to 2N0 tumors and 5.6 months (95% CI 4.4 to 6.8 months) in patients with T3N0 disease (p < 0.0001). The median DSS was not reached in patients with T2N0 or T3N0 GBCA and no RD, while it was 22 months (95% CI 0 to 58 months) in patients with a T1b to 2N0 and local RD, and 17.7 months (95% CI 0 to 51.5 months) in patients with a T3N0 and local RD (p ¼ 0.003) (Fig. 3) .
Univariate and multivariate analyses to predict residual disease, disease-free survival, and diseasespecific survival
Residual disease
The univariate analysis of patients treated with complete resection (n ¼ 116) is shown in Table 4 . Of note, the type of cholecystectomy was significantly correlated with T stage (p ¼ 0.001). Multivariate analysis showed that T stage was the only independent predictor factor of RD (p ¼ 0.015) (odds ratio [OR] 2.7, 95% CI 1.21 to 6.1) ( Table 4) .
Disease-free survival
The univariate analysis included 115 patients and is shown in Table 5 . One patient was excluded because the time to recurrence was not known. Multivariate analysis showed that tumor grade or differentiation (HR 4.0, 95% CI 1.55 to 10.8) (p ¼ 0.03) and any RD (HR 3.3, 95% CI 1.9 to 5.7) (p ¼ 0.0003) were independent predictors factors of DFS (Table 5) .
Disease-specific survival
This analysis included 116 patients and is shown in (p ¼ 0.01), and positive lymph nodes (HR 2.24, 95% CI 1.2 to 3.99) were independent predictors factors of DSS (Table 5) .
DISCUSSION
The incidence of IGBCA after cholecystectomy for presumed benign disease has increased during the past several years and currently is a common presentation. 14, 17 Re-exploration and definitive resection are recommended in select patients who do not present with any evidence of disseminated disease at restaging. [18] [19] [20] The goals of resection are, first, to improve survival by resecting all areas of possible RD, and second, to stage the disease completely. 4, 21 The population of this study was similar to that of studies in previous publications of IGBCA. 6, [22] [23] [24] Of the patients who underwent laparoscopic cholecystectomy for gallstones and were diagnosed with an adenocarcinoma invading the perimuscular connective tissue, most were female. More importantly, a high incidence (61%) of RD was observed in patients undergoing definitive surgery and in those who were treated with curative intent (55%). Most patients had RD involving the gallbladder bed, followed by lymph nodes, and common bile duct. These findings also confirmed that although intraoperative evaluation is a key element of the staging process and for determining the extent of required surgery (ie, resection of common bile duct), the real extent of disease is often determined only by the final pathologic analysis. This is evident in that 19 (16.4%) patients had unsuspected distant metastases on final pathologic examination in the liver, port sites, or peritoneum after undergoing complete resection.
Two previous multicenter studies have shown a similar rate and location of RD. 6, 7 The first evaluated 115 patients with IGBCA treated at 6 centers of North and South America, and Europe 6 ; the second included 188 patients (148 treated with complete resection) who underwent re-exploration at 21 centers in France. 7 Residual disease was found in 60.8% and 64% of patients, respectively, and mainly involved lymph nodes, common bile duct, and the liver. However, this study differs from these 2 studies in several aspects. This is the largest series from a single center, which, compared with multicenter studies, decreases bias related to patient selection and treatment and allows for a more thorough assessment of outcomes. In addition, this is the first study that definitively establishes T stage as an independent predictor of RD and the presence of any RD as an independent determinant of survival in patients with IGBCA, using multivariate analysis with adequate follow-up.
The major finding of this study was that in patients with IGBCA submitted to definitive reoperation and resection, RD at any site was associated with an equally poor outcome with respect to cancer recurrence and survival. The adverse impact of residual cancer in regional lymph nodes or at distant sites on outcome is not surprising because these findings necessarily change the stage of disease. By contrast, local RD within the gallbladder fossa is not associated with any change in disease stage, yet survival in this patient subgroup was no different than that observed in patients with regional or distant RD. Other studies have shown that local RD adversely affects survival, 6 ,10 but this is the first analysis to show that RD at local or regional sites reduces overall survival to that seen in stage IV disease. Likewise, the differences in survival based on location of RD, while not significant in this analysis, require confirmation in larger series to ensure against the confounding influence of type 2 error.
This study raises concerns regarding the current staging and treatment approach in patients with IGBCA. Residual disease in the liver bed, particularly in the setting of T2 tumors, would suggest inaccuracies in the initial assessment of the T stage or the presence of metastatic disease. In a study of 20 patients with T2 invasive tumors submitted to single-stage resection, Endo and colleagues 25 showed that 25% had discontiguous microscopic disease within the liver parenchyma, which was associated with a significant reduction in survival. Similar results were reported by Wakai and associates 26 in a larger series of patients submitted to a single-stage resection. In the setting of a 2-stage resection, it is impossible to know if local RD is the result of metastatic disease or more advanced T stage, unrecognized on initial assessment. Regardless of the mechanism, the presence of RD at both local and regional sites seems to be the clinical equivalent of distant metastatic disease. The absence of any survival difference among the subgroups stratified by RD location supports this assertion.
The results are both surprising and disappointing because the goal of reoperation and resection in this setting is clearance of residual local or regional disease; however, the efficacy of resection alone in patients with known RD is now called into question. Although this study does not specifically analyze the role of neoadjuvant and adjuvant therapies in gallbladder cancer, the data would suggest consideration of a change in treatment approach in patients with RD, given the high risk of recurrence and death. At the very least, adjuvant chemotherapy, previously not used routinely in this setting, should be examined in prospective trials as a means of improving outcomes. Alternatively, a neoadjuvant approach, targeting patients with a high risk of having RD, might help select patients most likely to benefit from reoperation and definitive resection. Whatever approach is ultimately adopted, it is clear that resection alone is inadequate therapy in many patients. Neoadjuvant therapy is attractive for many reasons, particularly because it may spare some patients an unnecessary operation; however, nonoperative identification of RD may represent a challenge in many patients. The T stage of the initial cholecystectomy was the most powerful predictor and the only independent predictor of RD (T3, 70%; T2, 48.3%; and T1b, 35.7%; p ¼ 0.015), and although potentially useful for identifying high-risk patients, it is clearly imperfect. Other clinical variables that might help stratify patients include type of cholecystectomy (laparoscopic converted to open), positive cholecystectomy margin, and poor differentiation. 6 Several limitations of this analysis must be recognized. First and foremost, the question of whether reoperation is appropriate for patients with gross local or regional RD, although suggested by the data presented, cannot be answered by this study, given its retrospective nature and the absence of a control group. Indeed, the weight of published evidence supports reoperation and definitive resection as the most effective therapy; this study does not change this recommendation but rather points out its limitations and argues for a re-evaluation of current treatment recommendations. Second, this singlecenter study has the typical advantage of using data from patients whose standards of care followed institutional standards that varied minimally from 1 patient to another. This results in less noise and a higher chance to correctly identify risk factors. Generalizability of our findings to other hospitals will depend on how patient selection and treatment criteria differ from 1 center to another. Third, the initial analysis of the gallbladder specimen was frequently performed elsewhere, after an incidental diagnosis, and although all specimens were re-examined by pathologists at MSKCC, potential inaccuracies in T-stage assessment, although unlikely, cannot be entirely excluded. In addition, the number of patients in each T stage was low, and the results must be confirmed in larger cohorts.
CONCLUSIONS
In conclusion, this is the largest series from a single center that evaluates predictors of RD in IGBCA and its role as a prognostic factor of DFS and DSS. Analysis of findings related to the initial cholecystectomy and a complete review of gallbladder specimen, specifically, T stage, tumor differentiation, and perineural invasion, can help to predict the risk of RD. Patients with RD after re-exploration and definitive resection had an increased risk of recurrence and a decreased DFS and DSS, and this was true for RD at all sites. Residual disease at local and regional sites was the clinical equivalent of stage IV disease. The results call into question the current staging of IGBCA and suggest a reevaluation of the current treatment approach in patients with RD.
